Drug Patents Expiring in 2034
1. Abilify Maintena Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10525057 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Mar, 2034
(9 years from now) | |
| US11648347 | OTSUKA PHARM CO LTD | Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient |
Apr, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 28, 2016 |
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: Treatment of schizophrenia
Dosage: FOR SUSPENSION, EXTENDED RELEASE
More Information on Dosage
ABILIFY MAINTENA KIT family patents
2. Abilify Mycite Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9270503 | OTSUKA | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
Sep, 2034
(9 years from now) | |
| US10097388 | OTSUKA | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
Sep, 2034
(9 years from now) | |
| US9787511 | OTSUKA | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
Sep, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patient
Dosage: TABLET
More Information on Dosage
ABILIFY MYCITE KIT family patents
3. Abraxane patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9511046 | BRISTOL-MYERS | Methods of treating pancreatic cancer |
Jan, 2034
(8 years from now) | |
|
US9511046 (Pediatric) | BRISTOL-MYERS | Methods of treating pancreatic cancer |
Jul, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-658) | Oct 11, 2015 |
| New Indication(I-676) | Sep 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Sep 06, 2020 |
| Orphan Drug Exclusivity(ODE-52) | Sep 06, 2020 |
| M(M-14) | Dec 06, 2022 |
| Pediatric Exclusivity(PED) | Jun 06, 2023 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: Treatment of pancreatic cancer
Dosage: POWDER
More Information on Dosage
ABRAXANE family patents
4. Adempas patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11203593 | BAYER HLTHCARE | Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
Feb, 2034
(9 years from now) | |
| US10662188 | BAYER HLTHCARE | Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate |
Feb, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 08, 2018 |
| Orphan Drug Exclusivity(ODE) | Oct 08, 2020 |
| Orphan Drug Exclusivity(ODE-53) | Oct 08, 2020 |
Drugs and Companies using RIOCIGUAT ingredient
NCE-1 date: 08 October, 2017
Market Authorisation Date: 08 October, 2013
Treatment: Treatment of adults with pulmonary hypertension (pah), (who group 1), to improve exercise capacity, who functional class and to delay clinical worsening; Treatment of adults with persistent/recurrent ...
Dosage: TABLET
More Information on Dosage
ADEMPAS family patents
5. Adlyxin patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10201663 | SANOFI-AVENTIS US | Assembly for a drug delivery device |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2021 |
Drugs and Companies using LIXISENATIDE ingredient
NCE-1 date: 27 July, 2020
Market Authorisation Date: 27 July, 2016
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ADLYXIN family patents
6. Airduo Digihaler patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9066957 | TEVA PHARM | Dry powder inhaler |
Oct, 2034
(9 years from now) | |
| US9415008 | TEVA PHARM | Dry powder inhaler |
Oct, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: Treatment of asthma
Dosage: POWDER
More Information on Dosage
AIRDUO DIGIHALER family patents
7. Airduo Respiclick patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9066957 | TEVA PHARM | Dry powder inhaler |
Oct, 2034
(9 years from now) | |
| US9415008 | TEVA PHARM | Dry powder inhaler |
Oct, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 27, 2020 |
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: Treatment of asthma
Dosage: POWDER
More Information on Dosage
AIRDUO RESPICLICK family patents
8. Alkindi Sprinkle patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9649280 | ETON | Composition comprising hydrocortisone |
May, 2034
(9 years from now) | |
Drugs and Companies using HYDROCORTISONE ingredient
Market Authorisation Date: 29 September, 2020
Treatment: Treatment of adrenal insufficiency
Dosage: GRANULE
More Information on Dosage
ALKINDI SPRINKLE family patents
9. Alunbrig patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9611283 | TAKEDA PHARMS USA | Methods for inhibiting cell proliferation in ALK-driven cancers |
Apr, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
| New Indication(I-847) | May 22, 2023 |
| Orphan Drug Exclusivity(ODE) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE-142) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE-300) | May 22, 2027 |
Drugs and Companies using BRIGATINIB ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)
Dosage: TABLET
More Information on Dosage
ALUNBRIG family patents
10. Arikayce Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9566234 | INSMED INC | Systems for treating pulmonary infections |
Jan, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-214) | Sep 28, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Sep 28, 2030 |
Drugs and Companies using AMIKACIN SULFATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen
Dosage: SUSPENSION, LIPOSOMAL
More Information on Dosage
ARIKAYCE KIT family patents
11. Aubagio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186346 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Feb, 2034
(8 years from now) | |
|
US9186346 (Pediatric) | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Aug, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2017 |
| M(M-61) | Apr 30, 2024 |
| Pediatric Exclusivity(PED) | Oct 30, 2024 |
Drugs and Companies using TERIFLUNOMIDE ingredient
NCE-1 date: 31 October, 2023
Market Authorisation Date: 12 September, 2012
Treatment: Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or adm...
Dosage: TABLET
More Information on Dosage
AUBAGIO family patents
12. Austedo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9296739 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(9 years from now) | |
|
US9550780 (Pediatric) | TEVA BRANDED PHARM | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(9 years from now) | |
|
US11666566 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(9 years from now) | |
|
US9814708 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(9 years from now) | |
|
US9233959 (Pediatric) | TEVA BRANDED PHARM | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-751) | Aug 30, 2020 |
| New Chemical Entity Exclusivity(NCE) | Apr 03, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 03, 2024 |
| Orphan Drug Exclusivity(ODE-134) | Apr 03, 2024 |
| M(M-54) | Jun 24, 2024 |
| Pediatric Exclusivity(PED) | Dec 24, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
NCE-1 date: 25 December, 2023
Market Authorisation Date: 03 April, 2017
Treatment: NA
Dosage: TABLET
More Information on Dosage
AUSTEDO family patents
13. Austedo Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9550780 (Pediatric) | TEVA | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(9 years from now) | |
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 17 February, 2023
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
AUSTEDO XR family patents
14. Auvelity patent expiration
Can you believe AUVELITY received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9205083 | AXSOME | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
Nov, 2034
(9 years from now) | |
| US11298352 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11141388 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11524008 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10966941 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11298351 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10894047 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11617728 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10898453 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US9707191 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US10064857 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11291665 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11291638 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11311534 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US9763932 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US9408815 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10786469 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US11253492 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US9370513 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US9968568 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US9421176 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US9375429 | AXSOME | Compositions and methods comprising erythrohydroxybupropion and related compounds for improving the efficacy of dextromethorphan |
Nov, 2034
(9 years from now) | |
| US9474731 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US9486450 | AXSOME | Hydroxybupropion and related compounds as modulators of drug plasma levels |
Nov, 2034
(9 years from now) | |
| US11344544 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11357744 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11969421 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US9700553 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US9861595 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US10881657 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US9168234 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US9867819 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US9278095 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10058518 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11617747 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US9457025 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(9 years from now) | |
| US11364233 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10874663 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10799497 | AXSOME | Combination of dextromethorphan and bupropion for treating depression |
Nov, 2034
(9 years from now) | |
| US11058648 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11273133 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10864209 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10806710 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10881624 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US10786496 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US11020389 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11185515 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10945973 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11382874 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11285146 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11497721 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11285118 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11510918 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10596167 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(9 years from now) | |
| US11439636 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US9314462 | AXSOME | Compositions and methods for increasing dextromethorphan plasma levels and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US9198905 | AXSOME | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US11426401 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11426370 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11419867 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10772850 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11273134 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11253491 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11234946 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10548857 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US11229640 | AXSOME | Combination of dextromethorphan and bupropion for treating depression |
Nov, 2034
(9 years from now) | |
| US10874665 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10933034 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10251879 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11517543 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11517542 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10092561 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(9 years from now) | |
| US11524007 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10894046 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11191739 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10874664 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10080727 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US11197839 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11147808 | AXSOME | Method of decreasing the fluctuation index of dextromethorphan |
Nov, 2034
(9 years from now) | |
| US11207281 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11141416 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11213521 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US12109178 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11129826 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11123343 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10966974 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US10512643 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US10463634 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US10105361 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US10105327 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphane and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US10092560 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US11478468 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11541048 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11541021 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11534414 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11779579 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11433067 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11596627 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US9238032 | AXSOME | Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan |
Nov, 2034
(9 years from now) | |
| US9457023 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US11090300 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US11096937 | AXSOME | Bupropion as a modulator of drug activity |
Nov, 2034
(9 years from now) | |
| US9700528 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| US10780066 | AXSOME | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
Nov, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 18, 2025 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 18 August, 2022
Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder; Dextromethorphan and bupropion in combination to increase dextromethorphan plasma levels
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
AUVELITY family patents
15. Ayvakit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9200002 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to KIT |
Oct, 2034
(9 years from now) | |
| US11827642 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to KIT |
Oct, 2034
(9 years from now) | |
| US9944651 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to kit |
Oct, 2034
(9 years from now) | |
| US9994575 | BLUEPRINT MEDICINES | Compositions useful for treating disorders related to kit |
Oct, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-863) | Jun 16, 2024 |
| New Indication(I-864) | Jun 16, 2024 |
| New Chemical Entity Exclusivity(NCE) | Jan 09, 2025 |
| New Indication(I-912) | May 22, 2026 |
| Orphan Drug Exclusivity(ODE-366) | Jan 09, 2027 |
| Orphan Drug Exclusivity(ODE-356) | Jun 16, 2028 |
| Orphan Drug Exclusivity(ODE-434) | May 22, 2030 |
Drugs and Companies using AVAPRITINIB ingredient
NCE-1 date: 10 January, 2024
Market Authorisation Date: 16 June, 2021
Treatment: Treatment of indolent systemic mastocytosis (ism); Treatment of advanced systemic mastocytosis, including patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with an associated...
Dosage: TABLET
More Information on Dosage
AYVAKIT family patents
16. Barhemsys patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9084765 | ACACIA | Use of amisulpride as an anti-emetic |
Feb, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2025 |
Drugs and Companies using AMISULPRIDE ingredient
NCE-1 date: 27 February, 2024
Market Authorisation Date: 26 February, 2020
Treatment: Prevention and treatment of post-operative nausea and vomiting
Dosage: SOLUTION
More Information on Dosage
BARHEMSYS family patents
17. Baxdela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12036219 | MELINTA | Methods of treating infections in overweight and obese patients using antibiotics |
Jun, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 19, 2022 |
| New Indication(I-815) | Oct 24, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Jun 19, 2027 |
Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient
NCE-1 date: 19 June, 2026
Market Authorisation Date: 19 June, 2017
Treatment: Treating an acute bacterial skin and skin structure infection (absssi) in an overweight or obese patient by intravenously (iv) administering 300mg of delafloxacin or a pharmaceutically acceptable salt...
Dosage: POWDER
More Information on Dosage
BAXDELA family patents
18. Bosulif patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11103497 | PF PRISM CV | Treatment of imatinib resistant leukemia |
Feb, 2034
(9 years from now) | |
|
US11103497 (Pediatric) | PF PRISM CV | Treatment of imatinib resistant leukemia |
Aug, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2017 |
| Orphan Drug Exclusivity(ODE) | Sep 04, 2019 |
| Orphan Drug Exclusivity(ODE-30) | Sep 04, 2019 |
| New Indication(I-759) | Dec 19, 2020 |
| Orphan Drug Exclusivity(ODE-163) | Dec 19, 2024 |
| New Indication(I-923) | Sep 26, 2026 |
| New Product(NP) | Sep 26, 2026 |
| Pediatric Exclusivity(PED) | Mar 26, 2027 |
| Orphan Drug Exclusivity(ODE-444) | Sep 26, 2030 |
Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient
Market Authorisation Date: 26 September, 2023
Treatment: A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject...
Dosage: CAPSULE; TABLET
More Information on Dosage
BOSULIF family patents
19. Brukinsa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9447106 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators |
Apr, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11142528 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(9 years from now) | |
| US10570139 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-871) | Aug 31, 2024 |
| New Indication(I-874) | Sep 14, 2024 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| New Indication(I-817) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-276) | Nov 14, 2026 |
| New Indication(I-936) | Mar 07, 2027 |
| Orphan Drug Exclusivity(ODE-371) | Aug 31, 2028 |
| Orphan Drug Exclusivity(ODE-370) | Sep 14, 2028 |
| Orphan Drug Exclusivity(ODE-274) | Jan 19, 2030 |
| Orphan Drug Exclusivity(ODE-467) | Mar 07, 2031 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: 15 November, 2023
Market Authorisation Date: 14 November, 2019
Treatment: Treatment of adult patients with small lymphocytic lymphoma; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy
Dosage: CAPSULE
More Information on Dosage
BRUKINSA family patents
20. Byfavo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9827251 | ACACIA | Dosing regimen for sedation with CNS 7056 (remimazolam) |
Jan, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 06, 2025 |
Drugs and Companies using REMIMAZOLAM BESYLATE ingredient
NCE-1 date: 06 October, 2024
Market Authorisation Date: 06 October, 2020
Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less
Dosage: POWDER
More Information on Dosage
BYFAVO family patents
21. Camzyos patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE50050 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(9 years from now) | |
| US9181200 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9585883 | BRISTOL | Pyrimidinedione compounds |
Jun, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-297) | Jun 15, 2026 |
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2027 |
| Orphan Drug Exclusivity(ODE-398) | Apr 28, 2029 |
Drugs and Companies using MAVACAMTEN ingredient
NCE-1 date: 28 April, 2026
Market Authorisation Date: 28 April, 2022
Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms
Dosage: CAPSULE
More Information on Dosage
CAMZYOS family patents
22. Caplyta patent expiration
Can you believe CAPLYTA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11026951 | INTRA-CELLULAR | Methods of treating bipolar disorder |
Dec, 2034
(9 years from now) | |
| US9956227 | INTRA-CELLULAR | Method for the treatment of residual symptoms of schizophrenia |
Dec, 2034
(9 years from now) | |
| US10960009 | INTRA-CELLULAR | Methods of treating schizophrenia and depression |
Dec, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-882) | Dec 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2024 |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
NCE-1 date: 21 December, 2023
Market Authorisation Date: 22 April, 2022
Treatment: Treatment of bipolar disorder i, bipolar disorder ii, or bipolar depression; Treatment of schizophrenia with improvement in residual symptoms of schizophrenia; Treatment of schizophrenia
Dosage: CAPSULE
More Information on Dosage
CAPLYTA family patents
23. Cibinqo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9035074 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(9 years from now) | |
| US9545405 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9549929 | PFIZER | Pyrrolo[2,3-D]pyrimidine derivatives |
Feb, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Feb 09, 2026 |
| New Chemical Entity Exclusivity(NCE) | Jan 14, 2027 |
Drugs and Companies using ABROCITINIB ingredient
NCE-1 date: 14 January, 2026
Market Authorisation Date: 14 January, 2022
Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable
Dosage: TABLET
More Information on Dosage
CIBINQO family patents
24. Clenpiq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10624879 | FERRING PHARMS INC | Liquid pharmaceutical composition |
Jun, 2034
(9 years from now) | |
| US11191753 | FERRING PHARMS INC | Liquid pharmaceutical composition |
Jun, 2034
(9 years from now) | |
| US9827231 | FERRING PHARMS INC | Liquid pharmaceutical composition |
Jun, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 15, 2021 |
Drugs and Companies using CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE ingredient
Market Authorisation Date: 28 November, 2017
Treatment: For cleansing of the colon as a preparation for colonoscopy; For cleansing the large intestine as a preparation for colonoscopy
Dosage: SOLUTION
More Information on Dosage
CLENPIQ family patents
25. Contrave patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10231964 | NALPROPION | Compositions and methods for weight loss in at risk patient populations |
Jul, 2034
(9 years from now) | |
| US10828294 | NALPROPION | Compositions and methods for weight loss in at risk patient populations |
Jul, 2034
(9 years from now) | |
| US10835527 | NALPROPION | Compositions and methods for reducing major adverse cardiovascular events |
Jul, 2034
(9 years from now) | |
| US11998542 | NALPROPION | Compositions and methods for reducing major adverse cardiovascular events |
Jul, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Sep 10, 2017 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 10 September, 2014
Treatment: For chronic weight management for treating overweight or obesity
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
CONTRAVE family patents
26. Cosela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10085992 | PHARMACOSMOS | Transient protection of normal cells during chemotherapy |
Mar, 2034
(9 years from now) | |
| US9487530 | PHARMACOSMOS | Transient protection of normal cells during chemotherapy |
Mar, 2034
(9 years from now) | |
| US10966984 | PHARMACOSMOS | Transient protection of normal cells during chemotherapy |
Mar, 2034
(9 years from now) | |
| US11717523 | PHARMACOSMOS | Transient protection of normal cells during chemotherapy |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2026 |
Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient
NCE-1 date: 12 February, 2025
Market Authorisation Date: 12 February, 2021
Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell l...
Dosage: POWDER
More Information on Dosage
COSELA family patents
27. Cotellic patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11087354 | GENENTECH INC | Combination therapies |
Jun, 2034
(9 years from now) | |
|
US11087354 (Pediatric) | GENENTECH INC | Combination therapies |
Dec, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 10, 2020 |
| Orphan Drug Exclusivity(ODE) | Nov 10, 2022 |
| Orphan Drug Exclusivity(ODE-101) | Nov 10, 2022 |
| M(M-278) | Jul 28, 2025 |
| New Indication(I-902) | Oct 28, 2025 |
| Pediatric Exclusivity(PED) | Jan 28, 2026 |
| Orphan Drug Exclusivity(ODE-416) | Oct 28, 2029 |
Drugs and Companies using COBIMETINIB FUMARATE ingredient
NCE-1 date: 28 January, 2025
Market Authorisation Date: 10 November, 2015
Treatment: Method of using cobimetinib for the treatment of melanoma
Dosage: TABLET
More Information on Dosage
COTELLIC family patents
28. Crexont patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10098845 | IMPAX | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | |
| US12178918 | IMPAX | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | |
| US12064521 | IMPAX | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | |
| US11622941 | IMPAX | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | |
| US12128141 | IMPAX | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | |
| US12178919 | IMPAX | Muco-adhesive, controlled release formulation of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | |
| US10292935 | IMPAX | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | |
| US11357733 | IMPAX | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | |
| US11666538 | IMPAX | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | |
| US10987313 | IMPAX | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | |
| US10973769 | IMPAX | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | |
| US10688058 | IMPAX | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 07, 2027 |
Drugs and Companies using CARBIDOPA; LEVODOPA ingredient
Market Authorisation Date: 07 August, 2024
Treatment: Treatment of parkinson's disease
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
CREXONT family patents
29. Dexycu Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10028965 | EYEPOINT PHARMS | Use of sustained release dexamethasone in post-cataract surgery inflammation |
May, 2034
(9 years from now) | |
| US10159683 | EYEPOINT PHARMS | Use of sustained release dexamethasone in post-cataract surgery inflammation |
May, 2034
(9 years from now) | |
| US10022502 | EYEPOINT PHARMS | Dose guides for injection syringe |
Jun, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 09, 2021 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 09 February, 2018
Treatment: Treatment of postoperative inflammation
Dosage: SUSPENSION
More Information on Dosage
DEXYCU KIT family patents
30. Dificid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9808530 | CUBIST PHARMS LLC | Composition of tiacumicin compounds |
May, 2034
(9 years from now) | |
|
US9808530 (Pediatric) | CUBIST PHARMS LLC | Composition of tiacumicin compounds |
Nov, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 27, 2016 |
| New Product(NP) | Jan 24, 2023 |
| New Patient Population(NPP) | Jan 24, 2023 |
| Pediatric Exclusivity(PED) | Jul 24, 2023 |
| Orphan Drug Exclusivity(ODE-367) | Jan 24, 2027 |
Drugs and Companies using FIDAXOMICIN ingredient
Market Authorisation Date: 24 January, 2020
Treatment: NA
Dosage: FOR SUSPENSION
More Information on Dosage
DIFICID family patents
31. Dilaudid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9248229 | FRESENIUS KABI USA | Packaging system for oxygen-sensitive drugs |
Mar, 2034
(9 years from now) | |
Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 January, 2020
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
DILAUDID family patents
32. Dilaudid-hp patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9248229 | FRESENIUS KABI USA | Packaging system for oxygen-sensitive drugs |
Mar, 2034
(9 years from now) | |
Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 January, 2020
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
DILAUDID-HP family patents
33. Doryx Mpc patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9295652 | MAYNE PHARMA | Controlled release doxycycline |
Oct, 2034
(9 years from now) | |
| US9511031 | MAYNE PHARMA | Controlled release doxycycline |
Oct, 2034
(9 years from now) | |
| US9446057 | MAYNE PHARMA | Controlled release doxycycline |
Dec, 2034
(9 years from now) | |
Drugs and Companies using DOXYCYCLINE HYCLATE ingredient
Market Authorisation Date: 19 December, 2014
Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet
Dosage: TABLET, DELAYED RELEASE
More Information on Dosage
DORYX MPC family patents
34. Durysta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9492316 | ABBVIE | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(9 years from now) | |
| US9980974 | ABBVIE | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 04, 2023 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 04 March, 2020
Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant
Dosage: IMPLANT
More Information on Dosage
DURYSTA family patents
35. Epclusa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9757406 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(8 years from now) | |
| US11707479 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(8 years from now) | |
| US11116783 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(8 years from now) | |
| US10086011 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(8 years from now) | |
|
US9757406 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(9 years from now) | |
|
US10086011 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(9 years from now) | |
|
US11707479 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(9 years from now) | |
|
US11116783 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 28, 2021 |
| New Dosing Schedule(D-177) | Nov 15, 2022 |
| New Patient Population(NPP) | Mar 19, 2023 |
| New Strength(NS) | Mar 19, 2023 |
| M(M-264) | Jul 14, 2023 |
| M(M-277) | Apr 27, 2025 |
| Orphan Drug Exclusivity(ODE-293) | Mar 19, 2027 |
| Orphan Drug Exclusivity(ODE-376) | Jun 10, 2028 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
NCE-1 date: 11 December, 2027
Market Authorisation Date: 19 March, 2020
Treatment: For the treatment of hepatitis c
Dosage: TABLET; PELLETS
More Information on Dosage
EPCLUSA family patents
36. Epinephrine patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10004700 | BPI LABS | More potent and less toxic formulations of epinephrine and methods of medical use |
Aug, 2034
(9 years from now) | |
| US10039728 | BPI LABS | More potent and less toxic formulations of epinephrine and methods of medical use |
Aug, 2034
(9 years from now) | |
| US9283197 | BPI LABS | More potent and less toxic formulations of epinephrine and methods of medical use |
Aug, 2034
(9 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 04 March, 2024
Treatment: Emergency treatment of allergic reactions (type 1), including anaphylaxis; A method of treating allergic reaction, anaphylaxis, anaphylactic shock, or combination thereof by an injection of at least o...
Dosage: SOLUTION
More Information on Dosage
EPINEPHRINE family patents
37. Evomela patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10040872 | ACROTECH BIOPHARMA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Jan, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Mar 10, 2023 |
| Orphan Drug Exclusivity(ODE-110) | Mar 10, 2023 |
Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient
Market Authorisation Date: 10 March, 2016
Treatment: NA
Dosage: POWDER
More Information on Dosage
EVOMELA family patents
38. Evzio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9517307 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Jul, 2034
(9 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 April, 2014
Treatment: Use of an auto injector to administer naloxone hcl
Dosage: SOLUTION
More Information on Dosage
EVZIO family patents
39. Evzio (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9517307 | KALEO INC | Devices and methods for delivering opioid antagonists including formulations for naloxone |
Jul, 2034
(9 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 19 October, 2016
Treatment: Use of an auto injector to administer naloxone hcl
Dosage: SOLUTION
More Information on Dosage
EVZIO (AUTOINJECTOR) family patents
40. Exblifep patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11124526 | ALLECRA THERAPS | Crystalline beta-lactamase inhibitor |
Nov, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 22, 2029 |
| Generating Antibiotic Incentives Now(GAIN) | Feb 22, 2034 |
Drugs and Companies using CEFEPIME HYDROCHLORIDE; ENMETAZOBACTAM ingredient
NCE-1 date: 22 February, 2033
Market Authorisation Date: 22 February, 2024
Treatment: Use of specified polymorphs of exblifep (cefepime and enmetazobactam) for treating complicated urinary tract infections (cuti) including pyelonephritis caused by designated susceptible microorganisms
Dosage: POWDER
More Information on Dosage
EXBLIFEP family patents
41. Exondys 51 patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10337003 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(9 years from now) | |
| US10364431 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(9 years from now) | |
| US9506058 | SAREPTA THERAPS INC | Compositions for treating muscular dystrophy |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 19, 2021 |
| Orphan Drug Exclusivity(ODE) | Sep 19, 2023 |
| Orphan Drug Exclusivity(ODE-122) | Sep 19, 2023 |
Drugs and Companies using ETEPLIRSEN ingredient
NCE-1 date: 19 September, 2020
Market Authorisation Date: 19 September, 2016
Treatment: Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Restoring an mrna reading frame to induce dystrophin protein production in ...
Dosage: SOLUTION
More Information on Dosage
EXONDYS 51 family patents
42. Fabhalta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9682968 | NOVARTIS | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof |
Jul, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10093663 | NOVARTIS | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof |
Jul, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-949) | Aug 07, 2027 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2028 |
| Orphan Drug Exclusivity(ODE-456) | Dec 05, 2030 |
Drugs and Companies using IPTACOPAN HYDROCHLORIDE ingredient
NCE-1 date: 06 December, 2027
Market Authorisation Date: 05 December, 2023
Treatment: Treatment of primary immunoglobulin a nephropathy (igan)
Dosage: CAPSULE
More Information on Dosage
FABHALTA family patents
43. Firdapse patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10793893 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
May, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 28, 2023 |
| New Patient Population(NPP) | Sep 29, 2025 |
| Orphan Drug Exclusivity(ODE-223) | Nov 28, 2025 |
Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient
NCE-1 date: 28 November, 2022
Market Authorisation Date: 28 November, 2018
Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine
Dosage: TABLET
More Information on Dosage
FIRDAPSE family patents
44. Fulvestrant patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9833459 | FRESENIUS KABI USA | Fulvestrant formulations |
Feb, 2034
(8 years from now) | |
| US10188663 | FRESENIUS KABI USA | Fulvestrant formulations |
Feb, 2034
(8 years from now) | |
| US9271990 | FRESENIUS KABI USA | Fulvestrant formulations |
May, 2034
(9 years from now) | |
Drugs and Companies using FULVESTRANT ingredient
Market Authorisation Date: 20 May, 2019
Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women
Dosage: SOLUTION
More Information on Dosage
FULVESTRANT family patents
45. Furoscix patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11433044 | SCPHARMACEUTICALS | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(9 years from now) | |
| US9884039 | SCPHARMACEUTICALS | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(9 years from now) | |
| US10272064 | SCPHARMACEUTICALS | Pharmaceutical formulations for subcutaneous administration of furosemide |
Apr, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 07, 2025 |
Drugs and Companies using FUROSEMIDE ingredient
Market Authorisation Date: 07 October, 2022
Treatment: Use of a liquid formulation comprising furosemide to treat congestion due to fluid overload (edema) in adults with nyha class ii/iii chronic heart failure
Dosage: SOLUTION
More Information on Dosage
FUROSCIX family patents
46. Ganzyk-rtu patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9486530 | EXELA PHARMA | Ganciclovir compositions and related methods |
Sep, 2034
(9 years from now) | |
Drugs and Companies using GANCICLOVIR ingredient
Market Authorisation Date: 17 February, 2017
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
GANZYK-RTU family patents
47. Giapreza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9220745 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(9 years from now) | |
| US11096983 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(9 years from now) | |
| US11559559 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(9 years from now) | |
| US10028995 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(9 years from now) | |
| US10493124 | LA JOLLA PHARMA | Angiotensin II alone or in combination for the treatment of hypotension |
Dec, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2022 |
Drugs and Companies using ANGIOTENSIN II ACETATE ingredient
NCE-1 date: 21 December, 2021
Market Authorisation Date: 23 December, 2021
Treatment: Treating high output shock with angiotensin ii by increasing mean arterial pressure in patients treated with catecholamines and reducing catecholamine use; Treating septic shock with angiotensin ii; I...
Dosage: SOLUTION
How can I launch a generic of GIAPREZA before it's drug patent expiration?
More Information on Dosage
GIAPREZA family patents
48. Givlaari patent expiration
Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10119143 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(9 years from now) | |
| US11028392 | ALNYLAM PHARMS INC | Compositions and methods for inhibiting expression of the ALAS1 gene |
Oct, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2024 |
| Orphan Drug Exclusivity(ODE-273) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 21 November, 2023
Market Authorisation Date: 20 November, 2019
Treatment: Treatment of acute hepatic porphyria
Dosage: SOLUTION
More Information on Dosage
GIVLAARI family patents
49. Glyxambi patent expiration
GLYXAMBI's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11833166 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(9 years from now) | |
|
US11090323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(9 years from now) | |
|
US10258637 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Jan 30, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| M(M-258) | Jul 03, 2022 |
| M(M-252) | Mar 30, 2023 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
NCE-1 date: 01 August, 2018
Market Authorisation Date: 30 January, 2015
Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Treating typ...
Dosage: TABLET
More Information on Dosage
GLYXAMBI family patents
50. Gocovri patent expiration
Can you believe GOCOVRI received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11903908 | SUPERNUS PHARMS | Methods of administering amantadine |
Jun, 2034
(9 years from now) | |
| US10646456 | SUPERNUS PHARMS | Methods of administering amantadine |
Jun, 2034
(9 years from now) | |
| US10154971 | SUPERNUS PHARMS | Methods of administering amantadine |
Dec, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-769) | Aug 24, 2020 |
| New Product(NP) | Aug 24, 2020 |
| Orphan Drug Exclusivity(ODE) | Aug 24, 2024 |
| Orphan Drug Exclusivity(ODE-153) | Aug 24, 2024 |
Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 August, 2017
Treatment: As adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes; Treatment of dyskinesia, decreasing off time, and increasing on time without troublesome...
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
GOCOVRI family patents
51. Harvoni patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10039779 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10039779 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-153) | Nov 12, 2018 |
| New Indication(I-718) | Nov 12, 2018 |
| New Indication(I-719) | Nov 12, 2018 |
| New Indication(I-720) | Nov 12, 2018 |
| New Dosing Schedule(D-158) | Feb 12, 2019 |
| New Dosing Schedule(D-159) | Feb 12, 2019 |
| New Dosing Schedule(D-160) | Feb 12, 2019 |
| New Chemical Entity Exclusivity(NCE) | Oct 10, 2019 |
| New Patient Population(NPP) | Apr 07, 2020 |
| New Dosing Schedule(D-177) | Nov 15, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
| ODE*(ODE*) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-136) | Apr 07, 2024 |
| Pediatric Exclusivity(PED) | Oct 07, 2024 |
| Orphan Drug Exclusivity(ODE-262) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-263) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-264) | Aug 28, 2026 |
Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient
NCE-1 date: 08 October, 2023
Market Authorisation Date: 28 August, 2019
Treatment: For treatment-naive genotype 1 patients with chronic hepatitis c virus (hcv) infection for a duration of 8-weeks
Dosage: TABLET
More Information on Dosage
HARVONI family patents
52. Hepzato patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9314561 | DELCATH SYSTEMS INC | Filter and frame apparatus and method of use |
Feb, 2034
(8 years from now) | |
| US9707331 | DELCATH SYSTEMS INC | Apparatus for removing chemotherapy compounds from blood |
Sep, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 14, 2026 |
| Orphan Drug Exclusivity(ODE-438) | Aug 14, 2030 |
Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient
Market Authorisation Date: 14 August, 2023
Treatment: NA
Dosage: POWDER
More Information on Dosage
HEPZATO family patents
53. Hetlioz patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9730910 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
May, 2034
(9 years from now) | |
| US11141400 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(9 years from now) | |
| US11786502 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(9 years from now) | |
| US10610511 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2021 |
| Orphan Drug Exclusivity(ODE-59) | Jan 31, 2021 |
| New Indication(I-850) | Dec 01, 2023 |
| Orphan Drug Exclusivity(ODE-330) | Dec 01, 2027 |
Drugs and Companies using TASIMELTEON ingredient
NCE-1 date: 31 January, 2018
Market Authorisation Date: 31 January, 2014
Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding th...
Dosage: CAPSULE
More Information on Dosage
HETLIOZ family patents
54. Hetlioz Lq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9730910 | VANDA PHARMS INC | Treatment of circadian rhythm disorders |
May, 2034
(9 years from now) | |
| US11141400 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(9 years from now) | |
| US10610511 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(9 years from now) | |
| US11786502 | VANDA PHARMS INC | Method of treatment |
Oct, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 01, 2023 |
| Orphan Drug Exclusivity(ODE-329) | Dec 01, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 01 December, 2020
Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding th...
Dosage: SUSPENSION
More Information on Dosage
HETLIOZ LQ family patents
55. Ibrance patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10723730 | PFIZER | Solid forms of a selective CDK4/6 inhibitor |
Feb, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-725) | Feb 19, 2019 |
| New Chemical Entity Exclusivity(NCE) | Feb 03, 2020 |
Drugs and Companies using PALBOCICLIB ingredient
NCE-1 date: 03 February, 2019
Market Authorisation Date: 01 November, 2019
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
IBRANCE family patents
56. Idhifa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9738625 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Aug, 2034
(9 years from now) | |
| US10093654 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Aug, 2034
(9 years from now) | |
| US9732062 | BRISTOL MYERS SQUIBB | Therapeutically active compounds and their methods of use |
Sep, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2022 |
| Orphan Drug Exclusivity(ODE) | Aug 01, 2024 |
| Orphan Drug Exclusivity(ODE-151) | Aug 01, 2024 |
Drugs and Companies using ENASIDENIB MESYLATE ingredient
NCE-1 date: 01 August, 2021
Market Authorisation Date: 01 August, 2017
Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation
Dosage: TABLET
More Information on Dosage
IDHIFA family patents
57. Imbruvica patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9540382 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Feb, 2034
(9 years from now) | |
|
US9296753 (Pediatric) | PHARMACYCLICS LLC | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
Apr, 2034
(9 years from now) | |
| US10695350 | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(9 years from now) | |
| US9795604 | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(9 years from now) | |
| US10463668 | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-680) | Feb 12, 2017 |
| New Indication(I-689) | Jul 28, 2017 |
| New Indication(I-702) | Jan 29, 2018 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2018 |
| New Indication(I-729) | Mar 04, 2019 |
| New Dosing Schedule(D-165) | May 06, 2019 |
| New Indication(I-736) | May 06, 2019 |
| New Indication(I-737) | May 06, 2019 |
| New Indication(I-741) | Jan 18, 2020 |
| New Indication(I-753) | Aug 02, 2020 |
| Orphan Drug Exclusivity(ODE-55) | Nov 13, 2020 |
| Orphan Drug Exclusivity(ODE-60) | Feb 12, 2021 |
| Orphan Drug Exclusivity(ODE-72) | Jul 28, 2021 |
| New Dosing Schedule(D-176) | Aug 24, 2021 |
| M(M-236) | Jan 25, 2022 |
| Orphan Drug Exclusivity(ODE-86) | Jan 29, 2022 |
| Orphan Drug Exclusivity(ODE-109) | Mar 04, 2023 |
| Orphan Drug Exclusivity(ODE-117) | May 06, 2023 |
| Orphan Drug Exclusivity(ODE-128) | Jan 18, 2024 |
| Orphan Drug Exclusivity(ODE) | Aug 02, 2024 |
| ODE*(ODE*) | Aug 02, 2024 |
| Orphan Drug Exclusivity(ODE-152) | Aug 02, 2024 |
| M(M-14) | Aug 24, 2025 |
| New Product(NP) | Aug 24, 2025 |
| New Patient Population(NPP) | Aug 24, 2025 |
| Pediatric Exclusivity(PED) | Feb 24, 2026 |
| Orphan Drug Exclusivity(ODE-405) | Aug 24, 2029 |
Drugs and Companies using IBRUTINIB ingredient
NCE-1 date: 24 February, 2025
Market Authorisation Date: 20 December, 2017
Treatment: Treatment of chronic graft versus host disease refractory to systemic therapy; Treatment of adult patients with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic...
Dosage: CAPSULE; TABLET; SUSPENSION
More Information on Dosage
IMBRUVICA family patents
58. Imcivree patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11129869 | RHYTHM | Pharmaceutical compositions |
Jul, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-892) | Jun 16, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 25, 2025 |
| Orphan Drug Exclusivity(ODE-336) | Nov 25, 2027 |
| Orphan Drug Exclusivity(ODE-402) | Jun 16, 2029 |
Drugs and Companies using SETMELANOTIDE ACETATE ingredient
NCE-1 date: 25 November, 2024
Market Authorisation Date: 25 November, 2020
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
IMCIVREE family patents
59. Imvexxy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11266661 | MAYNE PHARMA | Vaginal inserted estradiol pharmaceutical compositions and methods |
Feb, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 29, 2021 |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 29 May, 2018
Treatment: Treatment of a symptom of vulvar and vaginal atrophy
Dosage: INSERT
How can I launch a generic of IMVEXXY before it's drug patent expiration?
More Information on Dosage
IMVEXXY family patents
60. Inomax patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9279794 | MALLINCKRODT HOSP | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
Feb, 2034
(9 years from now) | |
|
US9279794 (Pediatric) | MALLINCKRODT HOSP | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
Aug, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-132) | Dec 21, 2013 |
| Pediatric Exclusivity(PED) | Jun 21, 2014 |
| M(M-167) | Oct 09, 2018 |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 23 December, 1999
Treatment: A method of providing nitric oxide therapy to a patient by compensating long-term sensitivity drift of electrochemical gas sensors used in systems for delivering therapeutic nitric oxide to a patient
Dosage: GAS
More Information on Dosage
INOMAX family patents
61. Izervay patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11491176 | ASTELLAS | Methods for treating or preventing ophthalmological conditions |
Jul, 2034
(9 years from now) | |
| US11273171 | ASTELLAS | Methods for treating or preventing ophthalmological conditions |
Jul, 2034
(9 years from now) | |
| US12016875 | ASTELLAS | Methods for treating or preventing ophthalmological conditions |
Jul, 2034
(9 years from now) | |
Drugs and Companies using AVACINCAPTAD PEGOL SODIUM ingredient
Market Authorisation Date: 04 August, 2023
Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by administerting avacincaptad pegol to the eye
Dosage: SOLUTION
More Information on Dosage
IZERVAY family patents
62. Jadenu patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9283209 | NOVARTIS PHARMS CORP | Oral formulations of deferasirox |
Nov, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jan 23, 2020 |
| Orphan Drug Exclusivity(ODE-39) | Jan 23, 2020 |
| M(M-239) | Dec 12, 2021 |
| M(M-241) | Jul 24, 2022 |
| M(M-263) | Jul 23, 2023 |
Drugs and Companies using DEFERASIROX ingredient
Market Authorisation Date: 30 March, 2015
Treatment: NA
Dosage: TABLET
More Information on Dosage
JADENU family patents
63. Jardiance patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11833166 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11666590 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11813275 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US9949997 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
May, 2034
(9 years from now) | |
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(9 years from now) | |
|
US10258637 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(9 years from now) | |
|
US11090323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(9 years from now) | |
|
US9949997 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Nov, 2034
(9 years from now) | |
|
US9949998 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Dec, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-159) | Jun 26, 2018 |
| M(M-160) | Jun 26, 2018 |
| M(M-161) | Jun 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Indication(I-869) | Aug 18, 2024 |
| M(M-82) | Feb 24, 2025 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| New Patient Population(NPP) | Jun 20, 2026 |
| New Indication(I-922) | Sep 21, 2026 |
Drugs and Companies using EMPAGLIFLOZIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 01 August, 2014
Treatment: Treating type 2 diabetes mellitus by assessing renal function and orally administering empagliflozin in a daily amount of 10 mg or 25 mg if the egfr>=45 ml/min/1.73 m2 and <60 ml/min/1.73 m2, wherein ...
Dosage: TABLET
More Information on Dosage
JARDIANCE family patents
64. Jublia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10828293 | BAUSCH | Anti-infective methods, compositions, and devices |
Oct, 2034
(9 years from now) | |
| US11654139 | BAUSCH | Anti-infective methods, compositions, and devices |
Oct, 2034
(9 years from now) | |
| US10342875 | BAUSCH | Stabilized efinaconazole compositions |
Oct, 2034
(9 years from now) | |
| US9662394 | BAUSCH | Stabilized efinaconazole compositions |
Oct, 2034
(9 years from now) | |
| US10864274 | BAUSCH | Stabilized efinaconazole formulations |
Oct, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 06, 2019 |
| New Patient Population(NPP) | Apr 27, 2023 |
Drugs and Companies using EFINACONAZOLE ingredient
NCE-1 date: 06 June, 2018
Market Authorisation Date: 06 June, 2014
Treatment: Antimycotic uses, specifically treatment of onychomycosis; Topical treatment of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes; Topical treatment of onychomycosis of the toe...
Dosage: SOLUTION
More Information on Dosage
JUBLIA family patents
65. Jylamvo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11771701 | SHORLA | Methotrexate formulation |
Oct, 2034
(9 years from now) | |
Drugs and Companies using METHOTREXATE ingredient
Market Authorisation Date: 29 November, 2022
Treatment: Treatment of adults with severe psoriasis with an oral solution of methotrexate
Dosage: SOLUTION
More Information on Dosage
JYLAMVO family patents
66. Kloxxado patent expiration
Can you believe KLOXXADO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11135155 | HIKMA | Liquid naloxone spray |
Aug, 2034
(9 years from now) | |
| US11975096 | HIKMA | Liquid naloxone spray |
Aug, 2034
(9 years from now) | |
| US11617713 | HIKMA | Liquid naloxone spray |
Aug, 2034
(9 years from now) | |
| US11628139 | HIKMA | Liquid naloxone spray |
Aug, 2034
(9 years from now) | |
| US10973814 | HIKMA | Liquid naloxone spray |
Aug, 2034
(9 years from now) | |
| US10722510 | HIKMA | Liquid naloxone spray |
Aug, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 29, 2024 |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 29 April, 2021
Treatment: Use of naloxone for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients
Dosage: SPRAY
More Information on Dosage
KLOXXADO family patents
67. Leqvio patent expiration
Can you believe LEQVIO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10125369 | NOVARTIS | PCSK9 iRNA compositions and methods of use thereof |
Aug, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: 22 December, 2025
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (hefh), by inhibiting expression of the pcsk9 gen...
Dosage: SOLUTION
More Information on Dosage
LEQVIO family patents
68. Liletta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10028858 | MEDICINES360 | Intrauterine systems, IUD insertion devices, and related methods and kits therefor |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 26, 2018 |
| New Indication(I-917) | Jun 29, 2026 |
Drugs and Companies using LEVONORGESTREL ingredient
Market Authorisation Date: 26 February, 2015
Treatment: A method for prevention of pregnancy
Dosage: SYSTEM
More Information on Dosage
LILETTA family patents
69. Litfulo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9617258 | PFIZER | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
Dec, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12077533 | PFIZER | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
Dec, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 23, 2028 |
Drugs and Companies using RITLECITINIB TOSYLATE ingredient
NCE-1 date: 24 June, 2027
Market Authorisation Date: 23 June, 2023
Treatment: Method of treating severe alopecia areata in adults and adolescents 12 years and older by administering ritlectinib
Dosage: CAPSULE
More Information on Dosage
LITFULO family patents
70. Lodoco patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10130585 | AGEPHA PHARMA FZ | Methods of treating and/or preventing cardiovascular disease |
May, 2034
(9 years from now) | |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 16 June, 2023
Treatment: A method of treating cardiovascular disease
Dosage: TABLET
More Information on Dosage
LODOCO family patents
71. Lonsurf patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10457666 | TAIHO ONCOLOGY | Stable crystal form of tipiracil hydrochloride and crystallization method for the same |
Jun, 2034
(9 years from now) | |
| US9527833 | TAIHO ONCOLOGY | Stable crystal form of tipiracil hydrochloride and crystallization method for the same |
Jun, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9943537 | TAIHO ONCOLOGY | Antitumor agent and antitumor effect enhancer |
Sep, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 22, 2020 |
| New Indication(I-794) | Feb 22, 2022 |
| Orphan Drug Exclusivity(ODE-229) | Feb 22, 2026 |
Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient
NCE-1 date: 23 September, 2019
Market Authorisation Date: 22 September, 2015
Treatment: Treatment of metastatic colorectal cancer with bevacizumab in patients previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and i...
Dosage: TABLET
More Information on Dosage
LONSURF family patents
72. Loreev Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8999393 | ALMATICA | Sustained release formulations of lorazepam |
Jan, 2034
(8 years from now) | |
Drugs and Companies using LORAZEPAM ingredient
Market Authorisation Date: 27 August, 2021
Treatment: Once daily treatment of anxiety disorder in adults
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
LOREEV XR family patents
73. Lumisight patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9763577 | LUMICELL | Imaging agent for detection of diseased cells |
Sep, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2029 |
Drugs and Companies using PEGULICIANINE ACETATE ingredient
NCE-1 date: 17 April, 2028
Market Authorisation Date: 17 April, 2024
Treatment: A method comprising administering pegulicianine to a human and obtaining an image of a tumor bed after tumor resection to distinguish in situ cancer cells from healthy cells
Dosage: POWDER
More Information on Dosage
LUMISIGHT family patents
74. Luzu patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8980931 | BAUSCH | Method of evaluating pharmaceutical preparation containing luliconazole and index substance |
Apr, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2018 |
| New Patient Population(NPP) | Feb 20, 2021 |
Drugs and Companies using LULICONAZOLE ingredient
NCE-1 date: 14 November, 2017
Market Authorisation Date: 14 November, 2013
Treatment: NA
Dosage: CREAM
More Information on Dosage
LUZU family patents
75. Makena (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9789257 | COVIS | Needle assisted injection device having reduced trigger force |
Feb, 2034
(8 years from now) | |
Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient
Market Authorisation Date: 14 February, 2018
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
MAKENA (AUTOINJECTOR) family patents
76. Mavyret patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11484534 | ABBVIE | Methods for treating HCV |
Mar, 2034
(9 years from now) | |
| US10286029 | ABBVIE | Method for treating HCV |
Mar, 2034
(9 years from now) | |
|
US11484534 (Pediatric) | ABBVIE | Methods for treating HCV |
Sep, 2034
(9 years from now) | |
|
US10286029 (Pediatric) | ABBVIE | Method for treating HCV |
Sep, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-230) | Aug 06, 2021 |
| New Patient Population(NPP) | Apr 30, 2022 |
| New Chemical Entity Exclusivity(NCE) | Aug 03, 2022 |
| New Dosing Schedule(D-175) | Sep 26, 2022 |
| M(M-259) | Apr 10, 2023 |
| Orphan Drug Exclusivity(ODE-232) | Apr 30, 2026 |
| Orphan Drug Exclusivity(ODE-233) | Apr 30, 2026 |
| Orphan Drug Exclusivity(ODE-372) | Jun 10, 2028 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient
NCE-1 date: 11 December, 2027
Market Authorisation Date: 03 August, 2017
Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg; Treatment of chronic hepatitis c virus (hcv) ge...
Dosage: TABLET; PELLETS
More Information on Dosage
MAVYRET family patents
77. Mekinist patent expiration
Can you believe MEKINIST received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10869869 (Pediatric) | NOVARTIS | Method of adjuvant cancer treatment |
Feb, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-678) | Jan 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
| M(M-170) | Nov 20, 2018 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| Orphan Drug Exclusivity(ODE-48) | May 29, 2020 |
| New Indication(I-745) | Jun 22, 2020 |
| Orphan Drug Exclusivity(ODE-57) | Jan 08, 2021 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| M(M-246) | Oct 06, 2022 |
| Orphan Drug Exclusivity(ODE-148) | Jun 22, 2024 |
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| New Indication(I-895) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Sep 16, 2026 |
| New Indication(I-908) | Mar 16, 2026 |
| New Product(NP) | Mar 16, 2026 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
NCE-1 date: 22 December, 2024
Market Authorisation Date: 29 May, 2013
Treatment: NA
Dosage: TABLET
More Information on Dosage
MEKINIST family patents
78. Morphine Sulfate patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9072781 | FRESENIUS KABI USA | Morphine formulations |
Mar, 2034
(9 years from now) | |
| US9192608 | FRESENIUS KABI USA | Morphine formulations |
Mar, 2034
(9 years from now) | |
| US9248229 | FRESENIUS KABI USA | Packaging system for oxygen-sensitive drugs |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 02, 2024 |
Drugs and Companies using MORPHINE SULFATE ingredient
Market Authorisation Date: 30 October, 2013
Treatment: Management of chronic pain in patients requiring opioid analgesia
Dosage: SOLUTION
More Information on Dosage
MORPHINE SULFATE family patents
79. Natesto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11090312 | ACERUS | Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 28, 2017 |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 28 May, 2014
Treatment: Nasal administration of a testosterone gel to a patient to treat the patient for a condition associated with a deficiency or absence of endogenous testosterone
Dosage: GEL, METERED
More Information on Dosage
NATESTO family patents
80. Omidria patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US9486406 (Pediatric) | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Apr, 2034
(9 years from now) | |
|
US9066856 (Pediatric) | RAYNER SURGICAL | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
Apr, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 30, 2017 |
| New Patient Population(NPP) | Dec 08, 2020 |
| Pediatric Exclusivity(PED) | Jun 08, 2021 |
Drugs and Companies using KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 May, 2014
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
OMIDRIA family patents
81. Onzetra Xsail patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10076614 | CURRAX | Nasal delivery devices |
Oct, 2034
(9 years from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 27 January, 2016
Treatment: NA
Dosage: POWDER
More Information on Dosage
ONZETRA XSAIL family patents
82. Oriahnn (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10881659 | ABBVIE | Methods of treating heavy menstrual bleeding |
Mar, 2034
(9 years from now) | |
| US11045470 | ABBVIE | Methods of treating heavy menstrual bleeding |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 29, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
NCE-1 date: 23 July, 2022
Market Authorisation Date: 29 May, 2020
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)
Dosage: CAPSULE
More Information on Dosage
ORIAHNN (COPACKAGED) family patents
83. Orilissa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11707464 | ABBVIE | Methods of treating heavy menstrual bleeding |
Mar, 2034
(9 years from now) | |
| US11344551 | ABBVIE | Methods of treating heavy menstrual bleeding |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2023 |
Drugs and Companies using ELAGOLIX SODIUM ingredient
NCE-1 date: 23 July, 2022
Market Authorisation Date: 23 July, 2018
Treatment: Management of moderate to severe pain associated with endometriosis using 150 mg elagolix for up to 24 months; Use of elagolix 200 mg bid for 6 months to manage moderate to severe pain associated with...
Dosage: TABLET
How can I launch a generic of ORILISSA before it's drug patent expiration?
More Information on Dosage
ORILISSA family patents
84. Orserdu patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10420734 | STEMLINE THERAP | Method of treating cancer using selective estrogen receptor modulators |
Oct, 2034
(9 years from now) | |
| US10071066 | STEMLINE THERAP | Method of treating cancer using selective estrogen receptor modulators |
Oct, 2034
(9 years from now) | |
| US11779552 | STEMLINE THERAP | Method of treating cancer using selective estrogen receptor modulators |
Oct, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 27, 2028 |
Drugs and Companies using ELACESTRANT HYDROCHLORIDE ingredient
NCE-1 date: 27 January, 2027
Market Authorisation Date: 27 January, 2023
Treatment: Treatment of an er-positive breast cancer following at least one line of endocrine therapy
Dosage: TABLET
More Information on Dosage
ORSERDU family patents
85. Otezla patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10092541 | AMGEN INC | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
May, 2034
(9 years from now) | |
| US9872854 | AMGEN INC | Methods for the treatment of psoriatic arthritis using apremilast |
May, 2034
(9 years from now) | |
|
US9872854 (Pediatric) | AMGEN INC | Methods for the treatment of psoriatic arthritis using apremilast |
Nov, 2034
(9 years from now) | |
|
US10092541 (Pediatric) | AMGEN INC | Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast |
Nov, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-694) | Sep 23, 2017 |
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2019 |
| New Indication(I-803) | Jul 19, 2022 |
| M(M-257) | Apr 10, 2023 |
| New Indication(I-884) | Dec 20, 2024 |
| Orphan Drug Exclusivity(ODE-248) | Jul 19, 2026 |
| M(M-299) | Jul 20, 2026 |
| Pediatric Exclusivity(PED) | Jan 20, 2027 |
| New Patient Population(NPP) | Apr 25, 2027 |
Drugs and Companies using APREMILAST ingredient
NCE-1 date: 20 January, 2026
Market Authorisation Date: 21 March, 2014
Treatment: Treatment of psoriasis using a dosage titration schedule; Treatment of psoriatic arthritis with apremilast using a dosage titration schedule and a second active agent
Dosage: TABLET
More Information on Dosage
OTEZLA family patents
86. Oxbryta patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9248199 | GLOBAL BLOOD THERAPS | 1:1 adducts of sickle hemoglobin |
Jan, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 25, 2024 |
| Orphan Drug Exclusivity(ODE-281) | Nov 25, 2026 |
| Orphan Drug Exclusivity(ODE-394) | Dec 17, 2028 |
Drugs and Companies using VOXELOTOR ingredient
NCE-1 date: 26 November, 2023
Market Authorisation Date: 14 October, 2022
Treatment: Treatment of sickle cell disease by administering voxelotor, as recited in claim 2
Dosage: TABLET; TABLET, FOR SUSPENSION
More Information on Dosage
OXBRYTA family patents
87. Oxlumo patent expiration
Can you believe OXLUMO received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11060093 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(9 years from now) | |
| US9828606 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(9 years from now) | |
| US10465195 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(9 years from now) | |
| US10487330 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10435692 | ALNYLAM PHARMS INC | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA |
Dec, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-901) | Oct 06, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 23, 2025 |
| Orphan Drug Exclusivity(ODE-339) | Nov 23, 2027 |
| Orphan Drug Exclusivity(ODE-415) | Oct 06, 2029 |
Drugs and Companies using LUMASIRAN SODIUM ingredient
NCE-1 date: 23 November, 2024
Market Authorisation Date: 23 November, 2020
Treatment: Treatment of primary hyperoxaluria type 1 (ph1)
Dosage: SOLUTION
More Information on Dosage
OXLUMO family patents
88. Parsabiv patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11959486 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(9 years from now) | |
| US9820938 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(9 years from now) | |
| US11162500 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(9 years from now) | |
| US10344765 | KAI PHARMS INC | Stable liquid formulation of AMG 416 (etelcalcetide) |
Jun, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 07, 2022 |
Drugs and Companies using ETELCALCETIDE ingredient
NCE-1 date: 07 February, 2021
Market Authorisation Date: 07 February, 2017
Treatment: A method of treating secondary hyperparathyroidism (shpt)
Dosage: SOLUTION
More Information on Dosage
PARSABIV family patents
89. Pluvicto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10398791 | NOVARTIS | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
Oct, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 23, 2027 |
Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient
NCE-1 date: 23 March, 2026
Market Authorisation Date: 23 March, 2022
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
PLUVICTO family patents
90. Procysbi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9173851 | HORIZON | Delayed release cysteamine bead formulation, and methods of making and using same |
Jun, 2034
(9 years from now) | |
| US9233077 | HORIZON | Delayed release cysteamine bead formulation, and methods of making and using same |
Jun, 2034
(9 years from now) | |
|
US9173851 (Pediatric) | HORIZON | Delayed release cysteamine bead formulation, and methods of making and using same |
Dec, 2034
(9 years from now) | |
|
US9233077 (Pediatric) | HORIZON | Delayed release cysteamine bead formulation, and methods of making and using same |
Dec, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Apr 30, 2016 |
| New Patient Population(NPP) | Aug 14, 2018 |
| Orphan Drug Exclusivity(ODE-45) | Apr 30, 2020 |
| M(M-216) | Dec 22, 2020 |
| Orphan Drug Exclusivity(ODE) | Aug 14, 2022 |
| Orphan Drug Exclusivity(ODE-97) | Aug 14, 2022 |
| ODE*(ODE*) | Dec 22, 2024 |
| Orphan Drug Exclusivity(ODE-162) | Dec 22, 2024 |
| Pediatric Exclusivity(PED) | Jun 22, 2025 |
Drugs and Companies using CYSTEAMINE BITARTRATE ingredient
Market Authorisation Date: 14 February, 2020
Treatment: NA
Dosage: GRANULE, DELAYED RELEASE; CAPSULE, DELAYED RELEASE
More Information on Dosage
PROCYSBI family patents
91. Qinlock patent expiration
Can you believe QINLOCK received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8461179 | DECIPHERA PHARMS | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
May, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2025 |
| Orphan Drug Exclusivity(ODE-298) | May 15, 2027 |
Drugs and Companies using RIPRETINIB ingredient
NCE-1 date: 15 May, 2024
Market Authorisation Date: 15 May, 2020
Treatment: NA
Dosage: TABLET
More Information on Dosage
QINLOCK family patents
92. Quviviq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9790208 | IDORSIA | Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Dec, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10023560 | IDORSIA | Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist |
Dec, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 07, 2027 |
| M(M-310) | Sep 30, 2027 |
Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient
NCE-1 date: 07 April, 2026
Market Authorisation Date: 07 April, 2022
Treatment: Treatment of insomnia
Dosage: TABLET
More Information on Dosage
QUVIVIQ family patents
93. Rayaldee patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10300078 | EIRGEN | Stabilized modified release vitamin D formulation and method of administering same |
Mar, 2034
(9 years from now) | |
| US9861644 | EIRGEN | Stabilized modified release vitamin D formulation and method of administering same |
Mar, 2034
(9 years from now) | |
| US11253528 | EIRGEN | Stabilized modified release Vitamin D formulation and method of administering same |
Mar, 2034
(9 years from now) | |
| US10357502 | EIRGEN | Stabilized modified release vitamin D formulation and method of administering same |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 17, 2019 |
Drugs and Companies using CALCIFEDIOL ingredient
Market Authorisation Date: 17 June, 2016
Treatment: NA
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
RAYALDEE family patents
94. Restasis Multidose patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9676525 | ABBVIE | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
Feb, 2034
(8 years from now) | |
| US9669974 | ABBVIE | Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids |
May, 2034
(9 years from now) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: NA
Dosage: EMULSION
More Information on Dosage
RESTASIS MULTIDOSE family patents
95. Rhopressa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9415043 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| US10588901 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| US9931336 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11185538 | ALCON LABS INC | Compositions for treating glaucoma or reducing intraocular pressure |
Mar, 2034
(9 years from now) | |
| US11020385 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2022 |
Drugs and Companies using NETARSUDIL MESYLATE ingredient
NCE-1 date: 18 December, 2021
Market Authorisation Date: 18 December, 2017
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS
More Information on Dosage
RHOPRESSA family patents
96. Rizafilm patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9301948 | GENSCO | Instantly wettable oral film dosage form without surfactant or polyalcohol |
Jul, 2034
(9 years from now) | |
Drugs and Companies using RIZATRIPTAN BENZOATE ingredient
Market Authorisation Date: 14 April, 2023
Treatment: NA
Dosage: FILM
More Information on Dosage
RIZAFILM family patents
97. Rocklatan patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9931336 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| US9993470 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| US9415043 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| US10588901 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11197853 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| US11185538 | ALCON LABS INC | Compositions for treating glaucoma or reducing intraocular pressure |
Mar, 2034
(9 years from now) | |
| US11020385 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Mar 12, 2022 |
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2022 |
Drugs and Companies using LATANOPROST; NETARSUDIL DIMESYLATE ingredient
NCE-1 date: 18 December, 2021
Market Authorisation Date: 12 March, 2019
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS
More Information on Dosage
ROCKLATAN family patents
98. Ryaltris patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10016443 | GLENMARK SPECLT | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US9078923 | GLENMARK SPECLT | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US9750754 | GLENMARK SPECLT | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US10517880 | GLENMARK SPECLT | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US10561672 | GLENMARK SPECLT | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US12064442 | GLENMARK SPECLT | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US9370483 | GLENMARK SPECLT | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US10376526 | GLENMARK SPECLT | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US9937189 | GLENMARK SPECLT | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US11400101 | GLENMARK SPECLT | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US10765686 | GLENMARK SPECLT | Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US10758550 | GLENMARK SPECLT | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US10646500 | GLENMARK SPECLT | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| US10548907 | GLENMARK SPECLT | Treatment of allergic rhinitis using a combination of mometasone and olopatadine |
Sep, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 13, 2025 |
Drugs and Companies using MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 January, 2022
Treatment: Treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate; Method of delivering a combination of olopatadine hydrochloride and m...
Dosage: SPRAY, METERED
More Information on Dosage
RYALTRIS family patents
99. Rybelsus patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10278923 | NOVO | Oral dosing of GLP-1 compounds |
May, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 20, 2022 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| M(M-252) | Jan 16, 2023 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 09 December, 2024
Treatment: Method of treating type 2 diabetes mellitus
Dosage: TABLET
More Information on Dosage
RYBELSUS family patents
100. Ryzumvi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11090261 | FAMYGEN LIFE SCI | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
Jan, 2034
(8 years from now) | |
| US9795560 | FAMYGEN LIFE SCI | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
Jan, 2034
(8 years from now) | |
| US10278918 | FAMYGEN LIFE SCI | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
Jan, 2034
(8 years from now) | |
| US11844858 | FAMYGEN LIFE SCI | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
Jan, 2034
(8 years from now) | |
| US10772829 | FAMYGEN LIFE SCI | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
Jan, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 25, 2026 |
Drugs and Companies using PHENTOLAMINE MESYLATE ingredient
Market Authorisation Date: 25 September, 2023
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
RYZUMVI family patents
101. Sinuva patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10406332 | INTERSECT ENT INC | Systems, devices, and method for treating a sinus condition |
Mar, 2034
(9 years from now) | |
| US10232152 | INTERSECT ENT INC | Systems, devices, and method for treating a sinus condition |
Nov, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 08, 2020 |
Drugs and Companies using MOMETASONE FUROATE ingredient
Market Authorisation Date: 08 December, 2017
Treatment: Treatment of nasal polyps in patients >=18 years of age who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant
Dosage: IMPLANT
More Information on Dosage
SINUVA family patents
102. Sofdra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9492429 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(9 years from now) | |
| US9895350 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(9 years from now) | |
| US9220707 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(9 years from now) | |
| US10383846 | BOTANIX SB | Method of dosing and use of soft anticholinergic esters |
Mar, 2034
(9 years from now) | |
| US11052067 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(9 years from now) | |
| US10952990 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(9 years from now) | |
| US10947192 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(9 years from now) | |
| US11034652 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(9 years from now) | |
| US11084788 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(9 years from now) | |
| US11026919 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(9 years from now) | |
| US10961191 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(9 years from now) | |
| US10959983 | BOTANIX SB | Formulation for soft anticholinergic analogs |
May, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 20, 2029 |
Drugs and Companies using SOFPIRONIUM BROMIDE ingredient
NCE-1 date: 20 June, 2028
Market Authorisation Date: 18 June, 2024
Treatment: Topical treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
Dosage: GEL, METERED
More Information on Dosage
SOFDRA family patents
103. Soolantra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9233117 | GALDERMA LABS LP | Treatment of inflammatory lesions of rosacea with ivermectin |
Mar, 2034
(9 years from now) | |
| US9782425 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(9 years from now) | |
| US10206939 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(9 years from now) | |
| US9233118 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(9 years from now) | |
| US9089587 | GALDERMA LABS LP | Treatment of papulopustular rosacea with ivermectin |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 19, 2017 |
Drugs and Companies using IVERMECTIN ingredient
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of inflammatory lesions of rosacea
Dosage: CREAM
More Information on Dosage
SOOLANTRA family patents
104. Sotylize patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10206895 | AZURITY | Sotalol compositions and uses of the same |
Apr, 2034
(9 years from now) | |
| US11013703 | AZURITY | Sotalol compositions and uses of the same |
Apr, 2034
(9 years from now) | |
| US11850222 | AZURITY | Sotalol compositions and uses of the same |
Nov, 2034
(9 years from now) | |
Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient
Market Authorisation Date: 22 October, 2014
Treatment: Indicated for the treatment of ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgement of the physician are life-threatening
Dosage: SOLUTION
More Information on Dosage
SOTYLIZE family patents
105. Spinraza patent expiration
Can you believe SPINRAZA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9926559 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Jan, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-226) | May 14, 2021 |
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 23, 2023 |
| Orphan Drug Exclusivity(ODE-127) | Dec 23, 2023 |
Drugs and Companies using NUSINERSEN SODIUM ingredient
NCE-1 date: 23 December, 2020
Market Authorisation Date: 23 December, 2016
Treatment: Treatment of spinal muscular atrophy
Dosage: SOLUTION
More Information on Dosage
SPINRAZA family patents
106. Spravato patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11446260 | JANSSEN PHARMS | Pharmaceutical composition of S-ketamine hydrochloride |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-840) | Jul 31, 2023 |
| NCE*(NCE*) | Mar 05, 2024 |
Drugs and Companies using ESKETAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 March, 2019
Treatment: Treatment of treatment-resistant depression in adults by nasally administering 56mg or 84mg of esketamine as a pharmaceutical composition in conjunction with an oral antidepressant
Dosage: SPRAY
How can I launch a generic of SPRAVATO before it's drug patent expiration?
More Information on Dosage
SPRAVATO family patents
107. Spritam patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11160786 | APRECIA PHARMS | Rapid disperse dosage form |
Mar, 2034
(9 years from now) | |
| US9339489 | APRECIA PHARMS | Rapid disperse dosage form containing levetiracetam |
Mar, 2034
(9 years from now) | |
| US9669009 | APRECIA PHARMS | Rapid disperse dosage form containing levetiracetam |
Mar, 2034
(9 years from now) | |
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 31 July, 2015
Treatment: Method of administering levetiracetam; Method of administering levetiracetam under fasted conditions
Dosage: TABLET, FOR SUSPENSION
More Information on Dosage
SPRITAM family patents
108. Sucraid patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9849161 | QOL MEDCL | Ultrapure hypoallergenic solutions of sacrosidase |
Feb, 2034
(8 years from now) | |
| US9255261 | QOL MEDCL | Ultrapure hypoallergenic solutions of sacrosidase |
Feb, 2034
(8 years from now) | |
| US9469847 | QOL MEDCL | Ultrapure hypoallergenic solutions of sacrosidase |
Feb, 2034
(8 years from now) | |
Drugs and Companies using SACROSIDASE ingredient
Market Authorisation Date: 09 April, 1998
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
SUCRAID family patents
109. Sunlenca patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9951043 | GILEAD SCIENCES INC | Therapeutic compounds |
Feb, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2027 |
Drugs and Companies using LENACAPAVIR SODIUM ingredient
NCE-1 date: 22 December, 2026
Market Authorisation Date: 22 December, 2022
Treatment: In combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection
Dosage: TABLET; SOLUTION
More Information on Dosage
SUNLENCA family patents
110. Synjardy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11833166 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11813275 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US9949997 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
May, 2034
(9 years from now) | |
|
US10258637 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(9 years from now) | |
|
US11090323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(9 years from now) | |
|
US9949997 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Nov, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 26, 2018 |
| M(M-174) | Mar 18, 2019 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| New Patient Population(NPP) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 26 August, 2015
Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of tr...
Dosage: TABLET
More Information on Dosage
SYNJARDY family patents
111. Synjardy Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11833166 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11813275 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US9949997 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
May, 2034
(9 years from now) | |
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(9 years from now) | |
|
US10258637 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(9 years from now) | |
|
US11090323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(9 years from now) | |
|
US9949997 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Nov, 2034
(9 years from now) | |
|
US9949998 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Dec, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| New Indication(I-739) | Dec 02, 2019 |
| M(M-296) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 09 December, 2016
Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of tr...
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
SYNJARDY XR family patents
112. Tafinlar patent expiration
Can you believe TAFINLAR received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US10869869 (Pediatric) | NOVARTIS | Method of adjuvant cancer treatment |
Feb, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-678) | Jan 08, 2017 |
| New Chemical Entity Exclusivity(NCE) | May 29, 2018 |
| M(M-170) | Nov 20, 2018 |
| Orphan Drug Exclusivity(ODE) | May 29, 2020 |
| Orphan Drug Exclusivity(ODE-47) | May 29, 2020 |
| New Indication(I-745) | Jun 22, 2020 |
| Orphan Drug Exclusivity(ODE-58) | Jan 09, 2021 |
| New Indication(I-778) | Apr 30, 2021 |
| New Indication(I-781) | May 04, 2021 |
| M(M-246) | Oct 06, 2022 |
| Orphan Drug Exclusivity(ODE-147) | Jun 22, 2024 |
| Orphan Drug Exclusivity(ODE-182) | Apr 30, 2025 |
| Orphan Drug Exclusivity(ODE-183) | May 04, 2025 |
| New Indication(I-894) | Jun 22, 2025 |
| Pediatric Exclusivity(PED) | Sep 16, 2026 |
| New Indication(I-908) | Mar 16, 2026 |
| New Product(NP) | Mar 16, 2026 |
| Orphan Drug Exclusivity(ODE-428) | Mar 16, 2030 |
Drugs and Companies using DABRAFENIB MESYLATE ingredient
NCE-1 date: 22 December, 2024
Market Authorisation Date: 29 May, 2013
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
TAFINLAR family patents
113. Talicia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9050263 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(8 years from now) | |
| US11931463 | REDHILL | All-in-one fixed-dose combination for treating Helicobacter pylori infection |
Feb, 2034
(8 years from now) | |
| US9603806 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(8 years from now) | |
| US10238606 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(8 years from now) | |
| US11135172 | REDHILL | Rifabutin-based compositions and methods for treating Helicobacter pylori infection |
Feb, 2034
(8 years from now) | |
| US9498445 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 01, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 01, 2027 |
Drugs and Companies using AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN ingredient
Market Authorisation Date: 01 November, 2019
Treatment: Treatment of h. pylori infection in adults; Treatment of helicobacter pylori infection in adults using specified dosage form
Dosage: CAPSULE, DELAYED RELEASE
More Information on Dosage
TALICIA family patents
114. Tazverik patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8410088 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Jan, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9688665 | EPIZYME INC | Methods of treating cancer |
Aug, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-835) | Jun 18, 2023 |
| New Indication(I-836) | Jun 18, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jan 23, 2025 |
| Orphan Drug Exclusivity(ODE-299) | Jan 23, 2027 |
| Orphan Drug Exclusivity(ODE-314) | Jun 18, 2027 |
Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient
NCE-1 date: 24 January, 2024
Market Authorisation Date: 23 January, 2020
Treatment: Method of treating epithelioid sarcoma
Dosage: TABLET
More Information on Dosage
TAZVERIK family patents
115. Tembexa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8962829 | EMERGENT BIODEFENSE | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof |
Oct, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10112909 | EMERGENT BIODEFENSE | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof |
Oct, 2034
(9 years from now) | |
| US9371344 | EMERGENT BIODEFENSE | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof |
Oct, 2034
(9 years from now) | |
| US10487061 | EMERGENT BIODEFENSE | Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof |
Oct, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 04, 2024 |
| Orphan Drug Exclusivity(ODE-354) | Jun 04, 2028 |
Drugs and Companies using BRINCIDOFOVIR ingredient
Market Authorisation Date: 04 June, 2021
Treatment: Method of treating human smallpox disease
Dosage: TABLET
More Information on Dosage
TEMBEXA family patents
116. Trijardy Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10258637 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11090323 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US11833166 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Apr, 2034
(9 years from now) | |
| US9949998 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Jun, 2034
(9 years from now) | |
|
US11090323 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(9 years from now) | |
|
US10258637 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Oct, 2034
(9 years from now) | |
|
US9949998 (Pediatric) | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
Dec, 2034
(9 years from now) | |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 January, 2020
Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin in combinatio...
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
TRIJARDY XR family patents
117. Trulance patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10011637 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11142549 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(9 years from now) | |
| US12146003 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(9 years from now) | |
| US11834521 | SALIX | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
Jun, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-764) | Jan 24, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jan 19, 2022 |
Drugs and Companies using PLECANATIDE ingredient
NCE-1 date: 19 January, 2021
Market Authorisation Date: 19 January, 2017
Treatment: NA
Dosage: TABLET
How can I launch a generic of TRULANCE before it's drug patent expiration?
More Information on Dosage
TRULANCE family patents
118. Truseltiq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10278969 | HELSINN HLTHCARE | Pharmaceutical dosage forms |
Dec, 2034
(9 years from now) | |
| US11160804 | HELSINN HLTHCARE | Pharmaceutical dosage forms |
Dec, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
| Orphan Drug Exclusivity(ODE-353) | May 28, 2028 |
Drugs and Companies using INFIGRATINIB PHOSPHATE ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
TRUSELTIQ family patents
119. Vafseo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11065237 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(9 years from now) | |
| US9701636 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(9 years from now) | |
| US10149842 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11857543 | AKEBIA | Compositions and methods for treating anemia |
Jun, 2034
(9 years from now) | |
| US9987262 | AKEBIA | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof |
Nov, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2029 |
Drugs and Companies using VADADUSTAT ingredient
NCE-1 date: 27 March, 2028
Market Authorisation Date: 27 March, 2024
Treatment: Treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months
Dosage: TABLET
More Information on Dosage
VAFSEO family patents
120. Velphoro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11446252 | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
Nov, 2034
(9 years from now) | |
| US11234938 | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
Nov, 2034
(9 years from now) | |
| US10624855 | VIFOR FRESENIUS | Pharmaceutical composition, comprising phosphate binder particles |
Nov, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 27, 2016 |
| New Patient Population(NPP) | Jul 01, 2027 |
| Pediatric Exclusivity(PED) | Jan 01, 2028 |
Drugs and Companies using FERRIC OXYHYDROXIDE ingredient
Market Authorisation Date: 27 November, 2013
Treatment: NA
Dosage: TABLET, CHEWABLE
More Information on Dosage
VELPHORO family patents
121. Veozah patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9422299 | ASTELLAS | Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
Mar, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10836768 | ASTELLAS | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
Mar, 2034
(9 years from now) | |
| US9987274 | ASTELLAS | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 12, 2028 |
Drugs and Companies using FEZOLINETANT ingredient
NCE-1 date: 13 May, 2027
Market Authorisation Date: 12 May, 2023
Treatment: Treatment of moderate to severe vasomotor symptoms due with menopause; Treatment of moderate to severe vasometer symptoms due to menopause
Dosage: TABLET
More Information on Dosage
VEOZAH family patents
122. Vogelxo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9622340 | UPSHER SMITH LABS | Flexible circuit board and method for manufacturing same |
Feb, 2034
(8 years from now) | |
| US9662340 | UPSHER SMITH LABS | Testosterone gel compositions and related methods |
Feb, 2034
(8 years from now) | |
| US8785426 | UPSHER SMITH LABS | Testosterone gel compositions and related methods |
Feb, 2034
(8 years from now) | |
| US9295675 | UPSHER SMITH LABS | Testosterone gel compositions and related methods |
Feb, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 04, 2017 |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 04 June, 2014
Treatment: Method for transdermal delivery of testosterone
Dosage: GEL, METERED; GEL
More Information on Dosage
VOGELXO family patents
123. Voranigo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9579324 | SERVIER | Therapeutically active compounds and their methods of use |
Jul, 2034
(9 years from now) | |
| US10172864 | SERVIER | Therapeutically active compounds and their methods of use |
Jul, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2029 |
| Orphan Drug Exclusivity(ODE-491) | Aug 06, 2031 |
Drugs and Companies using VORASIDENIB ingredient
NCE-1 date: 06 August, 2028
Market Authorisation Date: 06 August, 2024
Treatment: NA
Dosage: TABLET
More Information on Dosage
VORANIGO family patents
124. Vosevi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9296782 | GILEAD SCIENCES INC | Inhibitors of hepatitis C virus |
Jul, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11116783 | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jan, 2034
(8 years from now) | |
|
US11116783 (Pediatric) | GILEAD SCIENCES INC | Combination formulation of two antiviral compounds |
Jul, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 18, 2022 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient
NCE-1 date: 18 July, 2021
Market Authorisation Date: 18 July, 2017
Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor
Dosage: TABLET
More Information on Dosage
VOSEVI family patents
125. Wainua (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9127276 | ASTRAZENECA AB | Conjugated antisense compounds and their use |
May, 2034
(9 years from now) | |
| US9181549 | ASTRAZENECA AB | Conjugated antisense compounds and their use |
May, 2034
(9 years from now) | |
| US10683499 | ASTRAZENECA AB | Compositions and methods for modulating TTR expression |
Aug, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2028 |
| Orphan Drug Exclusivity(ODE-461) | Dec 21, 2030 |
Drugs and Companies using EPLONTERSEN SODIUM ingredient
NCE-1 date: 22 December, 2027
Market Authorisation Date: 21 December, 2023
Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis
Dosage: SOLUTION
More Information on Dosage
WAINUA (AUTOINJECTOR) family patents
126. Welireg patent expiration
Can you believe WELIREG received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9908845 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(9 years from now) | |
| US9969689 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(9 years from now) | |
| USRE49948 | MERCK SHARP DOHME | Aryl ethers and uses thereof |
Sep, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2026 |
| New Indication(I-931) | Dec 14, 2026 |
| Orphan Drug Exclusivity(ODE-364) | Aug 13, 2028 |
Drugs and Companies using BELZUTIFAN ingredient
NCE-1 date: 13 August, 2025
Market Authorisation Date: 13 August, 2021
Treatment: Treatment of adult patients with advanced renal cell carcinoma following a programmed death receptor-1 or programmed death-ligand inhibitor and a vascular endothelial growth factor tyrosine kinase inh...
Dosage: TABLET
More Information on Dosage
WELIREG family patents
127. Xarelto patent expiration
XARELTO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9539218 | JANSSEN PHARMS | Prevention and treatment of thromboembolic disorders |
Feb, 2034
(9 years from now) | |
|
US9539218 (Pediatric) | JANSSEN PHARMS | Prevention and treatment of thromboembolic disorders |
Aug, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-643) | Nov 04, 2014 |
| New Indication(I-660) | Nov 02, 2015 |
| New Indication(I-661) | Nov 02, 2015 |
| New Indication(I-662) | Nov 02, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
| New Dosing Schedule(D-168) | Oct 27, 2020 |
| New Indication(I-824) | Oct 11, 2021 |
| New Indication(I-810) | Oct 11, 2022 |
| M(M-284) | Mar 10, 2023 |
| New Indication(I-867) | Aug 23, 2024 |
| New Product(NP) | Dec 20, 2024 |
| Pediatric Exclusivity(PED) | Jun 20, 2025 |
Drugs and Companies using RIVAROXABAN ingredient
NCE-1 date: 24 February, 2024
Market Authorisation Date: 11 October, 2018
Treatment: Prophylaxis of pe, dvt and/or stroke in pediatric patients (>=50 kg) aged 2 years and older with congenital heart disease after fontan procedure with once daily, rapid-release tablet administered for ...
Dosage: TABLET
More Information on Dosage
XARELTO family patents
128. Xeglyze patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10292389 | HATCHTECH | Pediculicidal composition |
Dec, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2025 |
Drugs and Companies using ABAMETAPIR ingredient
NCE-1 date: 24 July, 2024
Market Authorisation Date: 24 July, 2020
Treatment: Topical treatment of head lice infestation in patients 6 months of age and older
Dosage: LOTION
More Information on Dosage
XEGLYZE family patents
129. Xeljanz Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10639309 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(9 years from now) | |
| US9937181 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(9 years from now) | |
| US11253523 | PFIZER | Tofacitinib oral sustained release dosage forms |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 06, 2017 |
| New Indication(I-761) | Dec 14, 2020 |
| New Indication(I-879) | Dec 14, 2024 |
Drugs and Companies using TOFACITINIB CITRATE ingredient
NCE-1 date: 06 November, 2016
Market Authorisation Date: 23 February, 2016
Treatment: A method of treating ulcerative colitis, by administering the formulation of tofacitinib of claims 1, 3, 8, 10, 15-20, 22, 27-31, 34-43, 50, 52, 59, 61, 68-71, 73, 75, 82-84 and 87-98
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
XELJANZ XR family patents
130. Xhance patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10076614 | OPTINOSE US INC | Nasal delivery devices |
Oct, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 18, 2020 |
| New Indication(I-940) | Mar 15, 2027 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 18 September, 2017
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
XHANCE family patents
131. Xipere patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9937075 | BAUSCH AND LOMB INC | Apparatus and methods for ocular injection |
May, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 22, 2024 |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 22 October, 2021
Treatment: NA
Dosage: SUSPENSION
More Information on Dosage
XIPERE family patents
132. Xphozah patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10940146 | ARDELYX INC | NHE3-binding compounds and methods for inhibiting phosphate transport |
Apr, 2034
(9 years from now) | |
| US10272079 | ARDELYX INC | NHE3-binding compounds and methods for inhibiting phosphate transport |
Apr, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2024 |
| New Product(NP) | Oct 17, 2026 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: 13 September, 2023
Market Authorisation Date: 17 October, 2023
Treatment: Treatment of hyperphosphatemia
Dosage: TABLET
More Information on Dosage
XPHOZAH family patents
133. Xyosted (autoinjector) patent expiration
Can you believe XYOSTED (AUTOINJECTOR) received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10881798 | ANTARES PHARMA INC | Needle assisted injection device having reduced trigger force |
Feb, 2034
(8 years from now) | |
| US11771646 | ANTARES PHARMA INC | Needle assisted jet injection administration of testosterone compositions |
Apr, 2034
(9 years from now) | |
| US11160751 | ANTARES PHARMA INC | Hematocrit modulation through needle assisted jet injection of testosterone |
Oct, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 28, 2021 |
Drugs and Companies using TESTOSTERONE ENANTHATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Method of administering testosterone enanthate subcutaneously
Dosage: SOLUTION
More Information on Dosage
XYOSTED (AUTOINJECTOR) family patents
134. Yonsa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9889144 | SUN PHARM | Abiraterone acetate formulation and methods of use |
Mar, 2034
(9 years from now) | |
| US10292990 | SUN PHARM | Abiraterone steroid formulation |
May, 2034
(9 years from now) | |
Drugs and Companies using ABIRATERONE ACETATE ingredient
Market Authorisation Date: 22 May, 2018
Treatment: Use in combination with methylprednisolone for the treatment of patients with prostate cancer
Dosage: TABLET
More Information on Dosage
YONSA family patents
135. Zegalogue patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11795204 | ZEALAND PHARMA | Glucagon analogues |
Jan, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2026 |
Drugs and Companies using DASIGLUCAGON HYDROCHLORIDE ingredient
NCE-1 date: 22 March, 2025
Market Authorisation Date: 22 March, 2021
Treatment: Method of treating diabetic hypoglycemia
Dosage: SOLUTION
More Information on Dosage
ZEGALOGUE family patents
136. Zegalogue (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11795204 | ZEALAND PHARMA | Glucagon analogues |
Jan, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2026 |
Drugs and Companies using DASIGLUCAGON HYDROCHLORIDE ingredient
NCE-1 date: 22 March, 2025
Market Authorisation Date: 22 March, 2021
Treatment: Method of treating diabetic hypoglycemia
Dosage: SOLUTION
More Information on Dosage
ZEGALOGUE (AUTOINJECTOR) family patents
137. Zelsuvmi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9855211 | LNHC | Topical compositions and methods of using the same |
Feb, 2034
(9 years from now) | |
| US11285098 | LNHC | Topical compositions and methods of using the same |
Feb, 2034
(9 years from now) | |
| US10258564 | LNHC | Topical compositions and methods of using the same |
Nov, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 05, 2029 |
Drugs and Companies using BERDAZIMER SODIUM ingredient
NCE-1 date: 06 January, 2028
Market Authorisation Date: 05 January, 2024
Treatment: Method of increasing release of nitric oxide from anhydrous alcohol gel; Method of topically reducing lesions with two separately stored components where one component includes water
Dosage: GEL
More Information on Dosage
ZELSUVMI family patents
138. Zerbaxa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8906898 | CUBIST PHARMS LLC | Solid forms of ceftolozane |
May, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9320740 | CUBIST PHARMS LLC | Ceftolozane-tazobactam pharmaceutical compositions |
Mar, 2034
(9 years from now) | |
| US11278622 | CUBIST PHARMS LLC | Ceftolozane antibiotic compositions |
Mar, 2034
(9 years from now) | |
| US10420841 | CUBIST PHARMS LLC | Ceftolozane antibiotic compositions |
Mar, 2034
(9 years from now) | |
| US8968753 | CUBIST PHARMS LLC | Ceftolozane-tazobactam pharmaceutical compositions |
Mar, 2034
(9 years from now) | |
| US9872906 | CUBIST PHARMS LLC | Ceftolozane antibiotic compositions |
Mar, 2034
(9 years from now) | |
| US10376496 | CUBIST PHARMS LLC | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
Sep, 2034
(9 years from now) | |
| US10933053 | CUBIST PHARMS LLC | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
Sep, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | Dec 19, 2024 |
| New Patient Population(NPP) | Apr 21, 2025 |
Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient
NCE-1 date: 20 December, 2023
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of ventilator-associated bacterial pneumonia (vabp); Complicated intra-abdominal infections (ciai), used in combination with metronidazole, in adult and pediatric patients (birth to less tha...
Dosage: POWDER
More Information on Dosage
ZERBAXA family patents
139. Zohydro Er patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10092559 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(9 years from now) | |
| US9713611 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(9 years from now) | |
| US9132096 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(9 years from now) | |
| US9486451 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(9 years from now) | |
| US9452163 | RECRO GAINESVILLE | Abuse resistant pharmaceutical compositions |
Sep, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 25, 2016 |
Drugs and Companies using HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 25 October, 2013
Treatment: Treatment of pain
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
ZOHYDRO ER family patents
140. Zuragard patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10688291 | ZUREX PHARMA | Medical skin applicator apparatus |
Dec, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 26, 2022 |
| M(M-268) | Jun 24, 2024 |
Drugs and Companies using ISOPROPYL ALCOHOL ingredient
Market Authorisation Date: 26 April, 2019
Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery
Dosage: SOLUTION
More Information on Dosage
ZURAGARD family patents
141. Zurnai (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10881798 | PURDUE PHARMA LP | Needle assisted injection device having reduced trigger force |
Feb, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 07, 2027 |
Drugs and Companies using NALMEFENE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 August, 2024
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ZURNAI (AUTOINJECTOR) family patents
142. Zurzuvae patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9512165 | BIOGEN INC | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
Apr, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10172871 | BIOGEN INC | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
Apr, 2034
(9 years from now) | |
| US10342810 | BIOGEN INC | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
Apr, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2028 |
Drugs and Companies using ZURANOLONE ingredient
NCE-1 date: 01 November, 2027
Market Authorisation Date: 31 October, 2023
Treatment: Method of treating postpartum depression
Dosage: CAPSULE
More Information on Dosage
ZURZUVAE family patents
143. Zynrelef Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10398686 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(9 years from now) | |
| US11253504 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(9 years from now) | |
| US9913909 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(9 years from now) | |
| US9744163 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(9 years from now) | |
| US9592227 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 12, 2024 |
| New Indication(I-933) | Jan 23, 2027 |
Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient
Market Authorisation Date: 12 May, 2021
Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarti...
Dosage: SOLUTION, EXTENDED RELEASE
More Information on Dosage
ZYNRELEF KIT family patents
List of large molecules
1. List of Prolia And Xgeva large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9328134 | AMGEN INC. | Carbohydrate phosphonate derivatives as modulators of glycosylation |
Feb, 2034
(9 years from now) | |
| US11952605 | AMGEN INC. | Methods for increasing mannose content of recombinant proteins |
Mar, 2034
(9 years from now) | |
| US11459595 | AMGEN INC. | Methods for increasing mannose content of recombinant proteins |
Mar, 2034
(9 years from now) | |
| US11319568 | AMGEN INC. | Methods for increasing mannose content of recombinant proteins |
Mar, 2034
(9 years from now) | |
| US11434514 | AMGEN INC. | Methods for increasing mannose content of recombinant proteins |
May, 2034
(9 years from now) | |
| US10894972 | AMGEN INC. | Methods for increasing mannose content of recombinant proteins |
May, 2034
(9 years from now) | |
| US9481901 | AMGEN INC. | Methods for increasing mannose content of recombinant proteins |
May, 2034
(9 years from now) | |
| US10421987 | AMGEN INC. | Methods for increasing mannose content of recombinant proteins |
May, 2034
(9 years from now) | |
| US11946085 | AMGEN INC. | Methods for increasing mannose content of recombinant proteins |
May, 2034
(9 years from now) | |
| US11299760 | AMGEN INC. | Use of monensin to regulate glycosylation of recombinant proteins |
Oct, 2034
(9 years from now) | |
| US10513723 | AMGEN INC. | Decreasing ornithine production to decrease high mannose glycoform content of recombinant proteins |
Dec, 2034
(9 years from now) | |
| US11254963 | AMGEN INC. | Increasing ornithine accumulation to increase high mannose glycoform content of recombinant proteins |
Dec, 2034
(9 years from now) | |
| US10227627 | AMGEN INC. | Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
Dec, 2034
(9 years from now) | |
| US10106829 | AMGEN INC. | Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
Dec, 2034
(9 years from now) | |
| US10655156 | AMGEN INC. | Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
Dec, 2034
(9 years from now) | |
| US10907186 | AMGEN INC. | Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins |
Dec, 2034
(9 years from now) |
Ingredients: DENOSUMAB
2. List of Lucentis large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9765379 | GENENTECH, INC. | Harvest operations for recombinant proteins |
Mar, 2034
(9 years from now) |
Ingredients: RANIBIZUMAB
3. List of Actemra large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10676710 | GENENTECH, INC. | Cell culture compositions with antioxidants and methods for polypeptide production |
Mar, 2034
(9 years from now) | |
| US10829732 | GENENTECH, INC. | Cell culture compositions with antioxidants and methods for polypeptide production |
Mar, 2034
(9 years from now) | |
| US10017732 | GENENTECH, INC. | Cell culture compositions with antioxidants and methods for polypeptide production |
Dec, 2034
(9 years from now) |
Ingredients: TOCILIZUMAB
4. List of Eylea large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US11332771 | REGENERON PHARMACEUTICALS, INC. | Serum-free cell culture medium |
Mar, 2034
(9 years from now) | |
| US11970724 | REGENERON PHARMACEUTICALS, INC. | Serum-free cell culture medium |
Mar, 2034
(9 years from now) | |
| USD858754 | REGENERON PHARMACEUTICALS, INC. | Syringe cap |
Sep, 2034
(9 years from now) | |
| US9315281 | REGENERON PHARMACEUTICALS, INC. | System and methods for use in dispensing biopharmaceutical materials |
Sep, 2034
(9 years from now) |
Ingredients: AFLIBERCEPT
5. List of Humira large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9499614 | ABBVIE INC. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
Mar, 2034
(9 years from now) | |
| US9550826 | ABBVIE INC. | Glycoengineered binding protein compositions |
Nov, 2034
(9 years from now) |
Ingredients: ADALIMUMAB
6. List of Avastin large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US9441035 | GENENTECH, INC. | Cell culture media and methods of antibody production |
Apr, 2034
(9 years from now) |
Ingredients: BEVACIZUMAB
7. List of Tysabri large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US10119976 | BIOGEN INC. | Method of assessing risk of PML |
May, 2034
(9 years from now) | |
| US10677803 | BIOGEN INC. | Method of assessing risk of PML |
May, 2034
(9 years from now) | |
| US11280794 | BIOGEN INC. | Method of assessing risk of PML |
May, 2034
(9 years from now) | |
| US10676772 | BIOGEN INC. | Control of protein glycosylation by culture medium supplementation and cell culture process parameters |
Aug, 2034
(9 years from now) | |
| US9994968 | BIOGEN INC. | Electrochemical etching apparatus |
Aug, 2034
(9 years from now) |
Ingredients: NATALIZUMAB